-
Japanese drugmaker Astellas Pharma Inc is looking to sell its dermatology portfolio that could be worth between $500 million and $1 billion, according to three people familiar with the situation.
-
U.S. safety regulators are investigating two 'unexplained' deaths that may be related to Eli Lilly’s Zyprexa injections, an antipsychotic drug.
-
Royalty Pharma's $8 billion bid for the Irish drug firm lapsed when it withdrew an appeal against a ruling by Ireland's regulator on takeover bids.
-
In a 5-3 vote, the Supreme Court ruled the Federal Trade Commission can challenge deals brand-name drug companies make with generic rivals that keep cheaper products off the market.
-
Johnson & Johnson agreed to acquire privately held drug developer Aragon Pharmaceuticals for as much as $1 billion.
-
Johnson & Johnson said on Monday that it would buy Aragon Pharmaceuticals, a private company that is running a mid-stage clinical trial for a prostate cancer drug, for $650 million in cash...
-
Elan shareholders approved a share buyback on Monday, meaning U.S.-based Royalty Pharma's hostile bid for the Irish drug firm will lapse unless a legal challenge it has mounted succeeds.
-
Japanese stocks edged mostly lower Monday, reflecting caution after a weak finish on Wall Street Friday and ahead of the Federal Reserve's policy decision later this week.
-
Amgen Inc , the world's largest biotechnology company, has plenty of room to grow despite a 43 percent jump in its share price over the past year, thanks to cost cuts, newer drugs and hefty share...
-
Aetna Inc said on Saturday it has notified California's insurance regulator that it plans to stop selling health policies to individual consumers in the state at the end of 2013.
-
Royalty Pharma believes that the only reason Elan Corp Plc has announced a sales process is to deflect Royalty's own offer, the company's CEO said in a statement Friday morning.
-
After the Obama administration decided to allow the contraceptive to be sold over the counter without restrictions, drug makers are facing questions over how to market the pill to teens—or whether...
-
The highest U.S. court ruled Thursday biotech companies can’t patent your genes. But they can stake claim to derivatives made from the building blocks of nearly all living things.
-
The Securities and Exchange Commission on Thursday said it charged Revlon Inc with misleading shareholders about details of a "going-private" transaction, and the cosmetics and beauty care company...
-
Shares of perfume and beauty products seller Coty fell in their market debut--taking the gloss off the third-largest U.S. IPO this year.
-
U.S.-based Royalty Pharma said on Thursday that it did not appear to have the backing of Elan shareholders in a vote that is set to decide the fate of its hostile bid of up to $8 billion for the...
-
U.S.-based Royalty Pharma sought to have an appeal heard next week over conditions attached to its hostile bid for Irish drug firm Elan that threaten to scupper the $8 billion deal.
-
Pfizer has reached a $2.15 billion settlement with the two companies over patent infringement on its acid-reflux drug Protonix.
-
Pfizer Inc. said Wednesday that it reached a settlement with Teva Pharmaceuticals Industries and Sun Pharmaceutical Industries over patent infringement.
-
Royalty Pharma, pursuing a hostile $8 billion takeover of Irish drugmaker Elan Corp Plc, moved on Tuesday to make sure it is not blocked by a potential $200 million share buyback and drug spinoff...
-
Walgreen Co. agreed to pay $80 million to settle civil charges related to improper prescription painkiller distribution, the U.S. Drug Enforcement Administration said.
-
Forest Laboratories Inc said on Tuesday it will add a representative of Carl Icahn as an independent member to its board, averting a new proxy battle with the billionaire investor.
-
Australia's Virtus Health Ltd became the first in-vitro fertilization company in the world to list, hitting the boards at a 7 percent premium to its offer price and sparking hope of renewed life...
-
A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was...
-
Irish drug firm Elan Corp Plc voluntarily dismissed its U.S. lawsuit against Royalty Pharma , the U.S. investment firm which increased its offer to take over Elan last week, a court filing showed...
-
The biopharmaceutical business is buying privately-held Pearl Therapeutics for up to $1.15 billion to build its portfolio of respiratory disease drugs.
-
An activist investor who has been campaigning for change at Alere Inc sent the company a letter on Monday calling for the health diagnostics and services company to sell three of its businesses,...
-
AstraZeneca is to buy U.S. respiratory drug specialist Pearl Therapeutics for up to $1.
-
Roche said the European Medicines Agency has approved RoACTEMRA to treat children with polyarticular juvenile idiopathic arthritis.
-
Investment partnership Royalty Pharma on Sunday urged a federal court in New York to allow it to proceed with a potential $8 billion bid for Irish drug company Elan Corp.
-
Royalty Pharma raised its hostile bid for Irish drug firm Elan to a potential $8 billion on Friday, after just 7.
-
A federal judge on Wednesday set a November 4 start for the criminal trial of Mathew Martoma, a former portfolio manager at hedge fund SAC Capital Advisors, on insider trading charges.
-
The health insurer agreed to raise its dividend by 32% to 28 cents and authorized another 110 million shares to be bought as part of an earlier repurchase program.
-
The German drugmaker said its bid for Conceptus has been successful and it plans to merge the U.S. pharmaceutical company with its subsidiary.
-
U.S.-based investment firm Royalty Pharma is unable to go ahead with its hostile $6.
-
EU antitrust regulators will fine nine drugmakers this month for blocking the entry of cheaper generic medicines to the market.
-
India's Sun Pharmaceutical Industries Ltd is in talks to buy Swedish drugmaker Meda AB for $5 billion-$6 billion to boost its generics business in developed markets, two sources with direct...
-
For consumers now on alert over a rogue strain of genetically modified wheat found in Oregon, the question is simple: How could this happen?
-
U.S. consumer groups plan to raise concerns on Wednesday about a proposed free trade agreement between the United States and the European Union, which they fear could weaken important government...
-
Amgen Inc, the world's largest biotechnology company, said it entered into a long-term collaboration with Astellas Pharma Inc and will form a joint venture with the Japanese drugmaker to provide...
-
The global biopharmaceutical business has entered into a definitive agreement to buy Omthera Pharmaceuticals in a deal valued at $323 million.
-
Among the companies with shares expected to actively trade in Tuesday's session are Tiffany & Co. (TIF), Omthera Pharmaceuticals Inc. (OMTH) and Canadian Solar Inc. (CSIQ).
-
Valeant Pharmaceuticals International Inc. (VRX) said the U.S. Food and Drug Administration rejected its new drug application for efinaconazole as a treatment for onychomycosis, citing questions...
-
Shares of Omthera Pharmaceuticals Inc. shot up 89% in premarket trade Monday after AstraZeneca PLC announced it had agreed to buy the specialty pharmaceutical firm for $12.70 a share, valuing the...
-
European stock markets posted solid gains on Tuesday, with banks in the driver's seat, as investors took inspiration from Asia, where a weaker yen spurred a rally for exporters.
-
AstraZeneca will acquire the Anglo-Swedish drug company' in a deal worth up to $443 million.
-
U.K.'s FTSE 100 index returned from a long weekend with solid gains on Tuesday, catching up with advances seen in Europe the prior day and overnight gains in Asia.
-
Pharmaceutical company AstraZeneca PLC (AZN.LN) Tuesday announced that the U.S. Court of Appeals for the Federal Circuit issued a temporary injunction blocking generic manufacturers from...
Account
